On July 7, 2025, KalVista Pharmaceuticals announced FDA approval for EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema, following promising results from a major clinical trial involving 136 patients across 20 countries. The treatment demonstrated significantly faster symptom relief compared to placebo.